MedPath

AICHI CANCER CENTER

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

25

Active:0
Completed:14

Trial Phases

4 Phases

Phase 1:2
Phase 2:9
Phase 3:1
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials

Not Applicable
13 (52.0%)
Phase 2
9 (36.0%)
Phase 1
2 (8.0%)
Phase 3
1 (4.0%)

Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx

Phase 2
Completed
Conditions
Head and Neck Cancer
First Posted Date
2005-10-21
Last Posted Date
2013-03-26
Lead Sponsor
Aichi Cancer Center
Target Recruit Count
50
Registration Number
NCT00243113
Locations
🇯🇵

Aichi Cancer Center, Nagoya, Aichi, Japan

🇯🇵

Hirosaki University, School of Medicine, Hirosaki, Aomori, Japan

🇯🇵

Chiba University, Chiba City, Chiba, Japan

and more 6 locations

Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer

Phase 2
Conditions
Head and Neck Cancer
First Posted Date
2004-10-08
Last Posted Date
2013-05-15
Lead Sponsor
Aichi Cancer Center
Target Recruit Count
90
Registration Number
NCT00093665
Locations
🇯🇵

National Hospital Organization - Medical Center of Kure, Hiroshima, Japan

🇯🇵

Kanazawa University, Kanazawa, Japan

🇯🇵

Kyoto Prefectural University of Medicine, Kyoto, Japan

and more 4 locations

News

Olomorasib Plus Pembrolizumab Shows Promise in KRAS G12C-Mutated NSCLC

Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.